Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization.

NCT05659940 | Unknown

• 1 other identifier: 2022KYPJ226
• Study Type: observational
• Target: 66
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine whether a novel subset of neutrophils is correlated with corneal neovascularization in the patients suffered from ocular chemical injury.

Conditions

Corneal Neovascularization; Neutrophils

Outcome Measures

Primary Outcomes (1)

• Changes of angiogenic neutrophils ratio

  Peripheral blood is collected in EDTA coated tubes and the red blood cells are lysed. The cells are firstly blocked and then stained the neutrophil subset markers. Flow cytometric analysis is performed at BD LSRFortessa™ Cell Analyzer and cells are analyzed by FlowJo v10 software.

  Inclusion (Day1) and 1 week

Secondary Outcomes (1)

• Corneal Neovascularization Score

  Inclusion (Day1) and 1 week

Study Arms (2)

Healthy people

Healthy participants whose age and gender are consistent with CNV patients

CNV patients

Patients who are diagnosed ocular chemical injury coming to Zhongshan Eye Center, Sun Yat-sen University for medical care

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Outpatients who come to Sun Yat-sen University Zhongshan Ophthalmic Center for medical care and healthy people who are volunteers recruited from society

You may qualify if:

• Diagnosed ocular chemical injury with or without corneal neovascularization.

You may not qualify if:

• Those who are diagnosed ocular diseases except for chemical ocular injury, such as uveitis, retinopathy.
• Those who are diagnosed allergic disease, autoimmune diseases or hematological diseases, infectious disease, such as eczema, systemic lupus erythematosus (SLE), agranulocytosis and viral hepatitis.
• Those who took immunosuppressive treatments in the past 3 months.
• Pregnant or nursing women.
• Those who have serious heart, lung, liver or kidney diseases.
• Those who have serious systemic diseases.
• Those who performed ocular surgery (including cataract surgery) in recent three months.
• Those who have been enrolled in other interventional clinical studies at the same time.
• Those who are unable to complete the study according to the investigators' requirements.

Sponsors & Collaborators

• Zhongshan Ophthalmic Center, Sun Yat-sen University: lead

Study Sites (1)

Zhongshan Ophthalmic Center

Guangzhou, Guangdong, 510000, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Peripheral blood is collected in EDTA coated tube.

MeSH Terms

Conditions

Corneal Neovascularization

Condition Hierarchy (Ancestors)

Corneal Diseases; Eye Diseases; Neovascularization, Pathologic; Metaplasia; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Ziqi Yang

CONTACT

8618826227484; yangzq6@mail2.sysu.edu.cn

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 5, 2022
• First Posted: December 21, 2022
• Study Start: January 1, 2023
• Primary Completion: November 30, 2023
• Study Completion: November 30, 2023
• Last Updated: March 7, 2023

Record last verified: 2022-11

Locations

CN (1)